Wednesday, November 30, 2016

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

Nov 30 (Reuters) - Pfizer Inc said on Wednesday its

experimental biosimilar of Roche Holding AG's

blockbuster breast cancer treatment Herceptin met the main goal

in a key study.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)